

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

NCT05611801

Status	RECRUITING
Phase	Phase 3
Sponsor	Pfizer
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (15)

- Male participants of appropriate age and required minimum weight
- Participants aged 12 to 17 years must be at least 25 kgs at time of consent.
- Participants aged 6 to 11 years must be at least 19 kgs at time of consent.
- Minimum weight requirement for participants aged 1 to 5 years is to be determined.
- Participants with a diagnosis of severe hemophilia A or moderately severe to severe hemophilia B

... and 10 more (see full listing online)

Exclusion (16)

- Known coronary artery, thrombotic, or ischemic disease, or current evidence of congenital or acquired thrombophilic disease such as Anti-thrombin III deficiency, Factor V Leiden mutation, prothrombin 20210 mutation, protein C deficiency, protein S deficiency and antiphospholipid syndrome.
- Known planned surgical procedure during the planned study period
- Known hemostatic defect other than hemophilia A or B
- Abnormal hematology, renal or hepatic function laboratory results at screening
- Other acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator

... and 11 more (see full listing online)

Locations (66 total)

Intermountain - Primary Children's Hospital, Salt Lake City, Utah, United States
Arbesu Hematología, Mendoza, Argentina
Sydney Children's Hospital, Randwick, New South Wales, Australia

... and 63 more locations